Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption | Zendy

MarieAngélique De Scheerder | Zendy; Clarissa Van Hecke | Zendy; Henrik Zetterberg | Zendy; Dietmar Fuchs | Zendy; Nele De Langhe | Zendy; Sofie Rutsaert | Zendy; Bram Vrancken | Zendy; Wim Trypsteen | Zendy; Ytse Noppe | Zendy; Bea Van Der Gucht | Zendy; Jolanda Pelgrom | Zendy; Filip Van Wanzeele | Zendy; Sarah Palmer | Zendy; Philippe Lemey | Zendy; Magnus Gisslén | Zendy; Linos Vandekerckhove | Zendy

Open Access

Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption

Author(s) -

MarieAngélique De Scheerder,

Clarissa Van Hecke,

Henrik Zetterberg,

Dietmar Fuchs,

Nele De Langhe,

Sofie Rutsaert,

Bram Vrancken,

Wim Trypsteen,

Ytse Noppe,

Bea Van Der Gucht,

Jolanda Pelgrom,

Filip Van Wanzeele,

Sarah Palmer,

Philippe Lemey,

Magnus Gisslén,

Linos Vandekerckhove

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa003

Subject(s) - viral load , neopterin , biomarker , immune system , kynurenine , medicine , immunology , neuroinflammation , inflammation , kynurenine pathway , biology , virology , virus , tryptophan , biochemistry , amino acid

Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring analytical treatment interruption (ATI) in study participants. Little is known about the safety of ATI and its long-term impact on patient health.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research